Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150433 | 0.94 | NQO1 (0.52) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL14461578 | 0.91 | ESR1 (0.52) | NQO1CYP3A4ESR1AHR | |
| SCHEMBL1683212 | 0.88 | NQO1 (0.65) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL16959484 | 0.87 | NQO1 (0.46) | NQO1TP53CYP3A4AHRLTA4H | |
| SCHEMBL16951377 | 0.84 | NQO1 (0.42) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL9774077 | 0.84 | ALDH1A1 (0.50) | NQO1LTA4HMEN1KMT2ARECQL | |
| SCHEMBL16956758 | 0.84 | MAPT (0.42) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL16951845 | 0.84 | NQO1 (0.42) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL9503610 | 0.84 | TP53 (0.53) | NQO1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL17204333 | 0.84 | NQO1 (0.42) | NQO1TSHRTDP1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763602-B2 | Pyrrole derivatives as antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-07-27 | — | — | US | claimed |
| US-7691837-B2 | Pyrrole derivatives as antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| WO-2023230541-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-2723857-B1 | RECOMBINANT PRODUCTION SYSTEMS FOR AROMATIC MOLECULES | RHO RENEWABLES INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10125381-B2 | Recombinant prodcution systems for aromatic molecules | RHO RENEWABLES, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| CN-108570420-A | The recombinant production system of aromatic molecules | RHO可再生股份有限公司 | 2018-09-25 | — | — | CN | disclosed |
| US-20170253893-A1 | RECOMBINANT PRODCUTION SYSTEMS FOR AROMATIC MOLECULES | VIA BIOFUELS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9637763-B2 | Recombinant production systems for aromatic molecules | RHO RENEWABLES, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170080097-A1 | DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
| US-9580409-B2 | Modulators of opioid receptors and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2007074893-A1 | OXADIAZOLE DERIVATIVE, AND LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE OXADIAZOLE DERIVATIVE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-07-05 | — | — | WO | disclosed |
| US-20070149784-A1 | Oxadiazole derivative, and light emitting element, light emitting device, and electronic device using the oxadiazole derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-06-28 | — | — | US | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142504-A1 | Novel multi-branched polymer | NIPPON SODA CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142504-A1 | Novel multi-branched polymer | NIPPON SODA CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| CN-1668584-A | Pyrrole derivatives as antimycobacterial compounds | LUPIN LTD (IN) | 2005-09-14 | — | — | CN | disclosed |
| EP-1546097-A1 | PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS | Lupin Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| US-20050107370-A1 | Pyrrole derivatives as antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
| WO-2004026828-A1 | PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149784-A1 | Oxadiazole derivative, and light emitting element, light emitting device, and electronic device using the oxadiazole derivative | OXA1L, ADRA1D, CRY1 | NQO1 447/4885TSHR 1930/4885TDP1 3460/4885 |
| US-20050107370-A1 | Pyrrole derivatives as antimycobacterial compounds | PGLS, SDHA, SDHB | NQO1 207/4885TSHR 3161/4885TDP1 1455/4885 |
| US-20170080097-A1 | DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS | CCL2, CD63, CD69 | NQO1 3876/4885TSHR 1614/4885TDP1 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.